TITLE

INFLAMMATORY BOWEL DISEASE AND THE RISK OF FRACTURE

AUTHOR(S)
van Staa, T.P.; Cooper, C.; Probert, C.S.J.; Leufkens, H.G.M.; Javaid, M.K.; Arden, N.
PUB. DATE
April 2003
SOURCE
Gut;Apr2003 Supplement 1, Vol. 52, pA12
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Patients with inflammatory bowel disease (IBD) have an increased risk of Iow bone mass, the pathogenesis of which is multifactorial. There are limited data on fracture. We therefore conducted a primary care based case-control study to determine the risk and major risk factors of fracture in IBD patients. 231 778 patients with a fracture and 231 778 age and sex matched controls were recruited from the General Practice Research Database. The database has been previously demonstrated to be a representative sample of the general population of England and Wales. Adjusted odds ratios (OR) were estimated from conditional logistic regression. The mean age of cases and controis was 51 years and 52.5% were women. A history of IBD was found in 1134 fracture cases, compared with 896 of the controls (adjusted OR 1.21; 95% CI 1.10 to 1.32). The OR was 1.72 (1.132.61) for vertebral fracture and 1.59 (1.14 to 2.23) for hip fracture. The risk of fracture was greater in patients with a history of Crohn's disease (OR 1.32 (1.13-1.53)) than in patients with ulcerative colitis (OR 1.13 (1.02-1.27)). The risk of fracture in patients with a history of IBD was significantly related to disease severity as assessed by the number of symptoms (OR in IBD patients without symptoms, 1.02 (090-1.17) 1 symptom, 1.66 (1.41-1.96); and ≥2 symptoms, 1.74 (1.43-12.12)). Similarly, severity assessed by medication demonstrated increasing fracture risks compared with untreated patients: aminosalicylates use 1.32 (1.14-1.54), oral corticosteroids 1.46 (1.18-1.82), and steroid sparing agents 1.86 (1.15-3.02). IBD patients with a history of bowel surgery did not have an increased risk of fracture (OR 1.03 (0.84-1.28)). Use of oral corticosteroids increased with severity of disease; after adjustment for oral corticosteroid use the risk of hip fracture remained elevated (OR 1.46 (1.04-2.04)). In conclusion, IBD patients have a higher risk of fractures, which is due to a combination of disease activity...
ACCESSION #
9747337

 

Related Articles

  • The association between corticosteroid use and development of fractures among IBD patients in a population-based database. Bernstein, Charles N.; Blanchard, James F.; Metge, Colleen; Yogendran, Marina // American Journal of Gastroenterology;Aug2003, Vol. 98 Issue 8, p1797 

    : ObjectiveBecause the rate of fracture among patients with inflammatory bowel disease (IBD) is only slightly higher than that in the general population, it is important to define high-risk groups worthy of diagnostic evaluation or prophylactic interventions. Corticosteroid use has been...

  • Bowel disease and fracture risk.  // GP: General Practitioner;3/1/2004, p32 

    The risk of hip fracture in patients with inflammatory bowel disease (IBD) is much higher than previously thought, according to a large Great Britain study. Researchers compared hip fracture rates in 16,550 IBD cases with 82,917 controls from the General Practice Research Database. They found...

  • Ibandronic acid unlikely choice for IBD-related fracture prevention.  // PharmacoEconomics & Outcomes News;4/19/2008, Issue 551, p6 

    The article discusses research being done on the use of ibandronate for inflammatory bowel disease- (IBD) related fracture prevention. It references a study by S. Kreck, L. Klaus et al, published in the January 2008 issue of "PharmaEconomics." According to study researchers, too few fractures...

  • Vertebral fractures in patients with inflammatory bowel disease COMPARED with a healthy population: a prospective case-control study. Angeles Vquez, Ma; Lopez, Enrique; Jos Montoya, Ma Jos; Giner, Merc; Prez-Temprano, Ramon; Prez-Cano, Ramon // BMC Gastroenterology;2012, Vol. 12 Issue 1, p47 

    Background: A prospective study was performed to compare the prevalence of morphometric vertebral fractures (MVF) between patients with inflammatory bowel disease (IBD) and healthy subjects and to identify predictive factors of fracture. Methods: A total of 107 patients with IBD (53 with Crohn's...

  • Cost Effectiveness of Ibandronate for the Prevention of Fractures in Inflammatory Bowel Disease-Related Osteoporosis. Kreck, Simon; Klaus, Jochen; Leidl, Reiner; von Tirpitz, Christian; Konnopka, Alexander; Matschinger, Herbert; König, Hans-Helmut // PharmacoEconomics;2008, Vol. 26 Issue 4, p311 

    Background: Osteoporosis is a frequent complication in patients with inflammatory bowel disease. Recent studies have shown bisphosphonates to considerably reduce fracture risk in patients with osteoporosis, and preventing fractures with bisphosphonates has been reported to be cost effective in...

  • Longitudinal Change in Bone Mineral Density in a Population-Based Cohort of Patients with Inflammatory Bowel Disease. Targownik, Laura; Leslie, William; Carr, Rachel; Clara, Ian; Miller, Norine; Rogala, Linda; Graff, Lesley; Walker, John; Bernstein, Charles // Calcified Tissue International;Nov2012, Vol. 91 Issue 5, p356 

    Persons with inflammatory bowel disease (IBD) are reported to have a high prevalence of osteoporosis and reduced bone mineral density (BMD) and to be at higher risk of fracture. The course of BMD loss over time is poorly characterized in persons with IBD. Eighty-six persons, stratified by age,...

  • Mandibular trabecular bone structure in adults with Crohn's disease. Jonasson, Grethe; Lindberg, Fredrik; Jorge, Alberto; Alstad, Torgny; Kashani, Hossein // Clinical Oral Investigations;Mar2014, Vol. 18 Issue 2, p423 

    Objectives: Crohn's disease (CD) is associated with reduced bone mineral density. The main objective of the present study was to assess the mandibular trabecular bone quality and to compare our findings with those among sex- and age-matched controls. Furthermore, background variables known to be...

  • A Double-Blind Placebo-Controlled Study of the Effects of the Bisphosphonate Risedronate on Bone Mass in Patients with Inflammatory Bowel Disease. Henderson, Sandra; Hoffman, Neville; Prince, Richard // American Journal of Gastroenterology;Jan2006, Vol. 101 Issue 1, p119 

    BACKGROUND: Low bone density and fractures are common in patients with inflammatory bowel disease (IBD). OBJECTIVE: To determine whether the bisphosphonate risedronate and calcium are safe and effective in preserving bone mass compared to calcium alone in IBD patients with low bone mass....

  • Pathological fractures in paediatric patients with inflammatory bowel disease. Wong, Sze; Catto-Smith, A.; Zacharin, Margaret // European Journal of Pediatrics;Feb2014, Vol. 173 Issue 2, p141 

    Paediatric inflammatory bowel disease (IBD), especially Crohn's disease (CD), is commonly associated with poor skeletal health, related to the direct effects of chronic inflammation, prolonged use of glucocorticoid (GC), poor nutrition, delayed puberty and low muscle mass. Low bone mineral...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics